blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP2303280

EP2303280 - COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATION AND HYPERKERATOTIC LESIONS [Right-click to bookmark this link]
StatusThe application has been withdrawn
Status updated on  05.08.2011
Database last updated on 05.07.2024
Most recent event   Tooltip20.01.2012Change - divisional application(s)published on 22.02.2012  [2012/08]
Applicant(s)For all designated states
Novelix Pharmaceuticals, Inc.
8008 Girard Avenue Suite 330
La Jolla CA 92037 / US
[2011/14]
Inventor(s)01 / JANSEN, M.D., Burkhard
1888 Viking Way
La Jolla, CA 92037 / US
 [2011/14]
Representative(s)Goddard, Christopher Robert, et al
Dehns
St Bride's House
10 Salisbury Square
London
EC4Y 8JD / GB
[N/P]
Former [2011/14]Goddard, Christopher Robert, et al
Dehns St Bride's House 10 Salisbury Square London
EC4Y 8JD / GB
Application number, filing date09767381.828.05.2009
[2011/14]
WO2009US45520
Priority number, dateUS20080057696P30.05.2008         Original published format: US 57696 P
[2011/14]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2009155070
Date:23.12.2009
Language:EN
[2009/52]
Type: A2 Application without search report 
No.:EP2303280
Date:06.04.2011
Language:EN
The application published by WIPO in one of the EPO official languages on 23.12.2009 takes the place of the publication of the European patent application.
[2011/14]
Search report(s)International search report - published on:EP11.02.2010
ClassificationIPC:A61K31/575, A61P17/06, A61P17/12, A61P17/02, A61P17/14, A61P35/00, A61K31/56, A61P17/00
[2011/14]
CPC:
A61K31/56 (EP,US); A61K47/10 (EP,US); A61K47/26 (EP,US);
A61K47/44 (EP,US); A61K9/0014 (EP,US); A61P17/00 (EP);
A61P17/02 (EP); A61P17/06 (EP); A61P17/12 (EP);
A61P17/14 (EP); A61P29/00 (EP); A61P35/00 (EP) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2011/14]
TitleGerman:ZUSAMMENSETZUNGEN UND VERFAHREN ZUR BEHANDLUNG VON ENTZÜNDUNG UND HYPERKERATOTISCHEN LÄSIONEN[2011/14]
English:COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATION AND HYPERKERATOTIC LESIONS[2011/14]
French:COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT D INFLAMMATION ET DE LÉSIONS HYPERKÉRATOTIQUES[2011/14]
Entry into regional phase24.12.2010National basic fee paid 
24.12.2010Designation fee(s) paid 
24.12.2010Examination fee paid 
Examination procedure24.12.2010Examination requested  [2011/14]
20.04.2011Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
29.06.2011Amendment by applicant (claims and/or description)
02.08.2011Application withdrawn by applicant  [2011/36]
Divisional application(s)EP11172000.9  / EP2371368
Request for further processing for:29.06.2011Request for further processing filed
29.06.2011Full payment received (date of receipt of payment)
Request granted
28.07.2011Decision despatched
Fees paidRenewal fee
11.05.2011Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[DXY]US7312205  (SELZER EDGAR [AT], et al) [DX] 1-10 * col. 1, lines 21-28 col. 5, lines 1-19; (Compound B) col. 10, line 41, Test #4 * [Y] 11-14;
 [X]WO2005077377  (UNIV MINNESOTA [US], et al) [X] 1-8 * page 7, lines 3-16 page 8, lines 3-11 page 71, lines 9-16 page 75, lines 8-12 pages 115-116, paragraphs 70-73 pages 129-132, example 4 *;
 [X]WO9832443  (MARIGEN SA [CH], et al) [X] 1-8 * claim 1, compound III claim 2 *;
 [Y]WO9614872  (CHINOIN GYOGYSZER ES VEGYESZET [HU], et al) [Y] 11-14 * page 3, lines 23-26 page 6, lines 6-15 page 17, example 1 *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.